TNFSF10 and chronic myelogenous leukemia, BCR-ABL1 positive: To confirm the results in vitro, we treated primary AML (N=8) and blast crisis chronic myeloid leukemia (BC-CML, N=7) primary cells with the Med and TRAIL combination for 48 h.